Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART2)

CompletedOBSERVATIONAL
Enrollment

171

Participants

Timeline

Start Date

January 25, 2023

Primary Completion Date

October 13, 2023

Study Completion Date

October 13, 2023

Conditions
Renal Cell Carcinoma
Interventions
DRUG

avelumab

as provided in real world practice

DRUG

axitinib

as provided in real world practice

Trial Locations (19)

466-8560

Nagoya University Hospital, Nagoya

036-8563

Hirosaki University Hospital, Hirosaki

830-0011

Kurume University Hospital, Kurume-shi

078-8510

Asahikawa Medical University Hospital, Asahikawa

060-8543

Sapporo Medical University Hospital, Sapporo

650-0017

Kobe University Hospital, Kobe

650-0047

Kobe City Medical Center General Hospital, Kobe

920-8641

Kanazawa University Hospital, Kanazawa

783-8505

Kochi Medical School Hospital, Nankoku

612-8555

National Hospital Organization Kyoto Medical Center, Kyoto

589-8511

Kindai University Hospital, Sayama

565-0871

Osaka University Hospital, Suita

330-8503

Jichi Medical University Saitama Medical Center, Saitama

160-8582

Keio University Hospital, Shinjuku-ku

641-8510

Wakayama Medical University Hospital, Wakayama

990-9585

Yamagata University Hospital, Yamagata

812-8582

Kyushu University Hospital, Fukuoka

734-8551

Hiroshima University Hospital, Hiroshima

602-8566

University Hospital Kyoto Prefectural University of Medicine, Kyoto

All Listed Sponsors
lead

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

INDUSTRY